

## Contents

Introduction .....	25
Leydig Cell Development.....	25
Fetal Leydig Cells.....	27
Neonatal Leydig Cells .....	27
Adult Leydig Cells .....	27
Steroidogenic Function of Leydig Cells .....	28
Androgen Synthesis via the Canonical Pathway .....	29
Androgen Synthesis via the Alternative Pathway.....	29
Estrogen Synthesis by Human Leydig Cells .....	30
Androgen Secretion by the Leydig Cells/Testis .....	30
Other Functions of the Leydig Cell .....	30
Regulation of Leydig Cell Development and Function .....	31
Leydig Cell Development.....	31
Regulation of Leydig Cell Activity.....	32
Clinical Aspects .....	34
Leydig Cell Aging .....	34
Leydig Cell Tumors.....	36
Leydig Cell Toxicology.....	38
Conclusions—Future Work .....	38
References .....	39


## Introduction

In all mammals, Leydig cells are the main source of the androgens required for development of the male phenotype, for germ cell production, and for male sex drive. The Leydig cells are essential, therefore, for masculinization, fertility, and reproductive health and, recent evidence would also suggest, for general adult wellbeing in the male [1]. In this chapter, the development, steroidogenic function and regulation of human Leydig cells will be summarized. Clinical aspects of aging and pathology related to Leydig cells will also be reviewed. The data presented is based, where possible, on information from the human, but there is a much larger database of rodent studies available and data from these studies is included where relevant.

## Leydig Cell Development

Leydig cells were first described by the German histologist Franz Leydig in 1850 as prominent clusters of cells lying between the seminiferous tubules in a variety of mammals [2]. Subsequently, Leydig cells have been shown to be the major functional cell type in the interstitial compartment of the testis, separated from the seminiferous tubules by the peritubular myoid cells (Fig. 2.1). Human Leydig cells are ovoid or polygonal in shape with eosinophilic cytoplasm, a euchromatic

P.J. O'Shaughnessy (✉)  
College of Medical Veterinary and Life Sciences,  
University of Glasgow, Bearsden Rd.,  
Glasgow G61 1QH, UK  
e-mail: peter.oshaughnessy@glasgow.ac.uk




**Fig. 2.1** Fetal testis. **a** Fetal mouse: low magnification of a semi-thin section showing seminiferous tubules (*ST*) and interstitial tissue (*I*). **b** Fetal mouse: higher magnification of (**a**) showing gonocytes (*G*) in the central part of the sex cord with the Sertoli cells (*S*) around the periphery. The peritubular myoid cells (*PMC*) form a concentric layer around the cord, and Leydig cells (*L*) are present within the interstitium. **c** Fetal human: immunohistochemically

labeled for the androgen receptor (*AR*) which is clearly expressed in *PMC* and in some interstitial cells. **d** Fetal human: immunohistochemically labeled for 3 $\beta$ -hydroxysteroid dehydrogenase (*HSD3B*) which is localized exclusively in the Leydig cells. In all photomicrographs, the bar represents 50  $\mu$ m. Adapted from O'Shaughnessy and Fowler [22]. (c) Society for Reproduction and Fertility (2011). Reproduced with permission

round eccentric nucleus with a peripheral distribution of heterochromatin, and a conspicuous nucleolus. The predominant cytoplasmic organelle is the smooth endoplasmic reticulum (SER), which is characteristically abundant in steroidogenic cells, with mitochondria and lipid droplets also numerous (Fig. 2.2). Crystals of Reinke are variably found in normal adult human Leydig cells, although their composition and significance remains unknown.

In all mammalian species so far studied, two populations of Leydig cells have been identified. A fetal population that arises soon after testis differentiation, and an adult population which develops before puberty [3]. Until recently, it was thought that the fetal population regressed as the adult population developed, but evidence

from the mouse suggests that the fetal cells remain present in the adult at about 10% of the total Leydig cell number [4]. In humans, blood levels of testosterone peak three times during development [5], and it has been suggested that this is evidence for three populations of Leydig cells in humans [6]. The first peak occurs at 12–14 weeks of gestation, during the fetal differentiation of Leydig cells [7, 8]. Testosterone levels then decline and are low for the remainder of gestation and the very early neonatal period. There is a second peak of testosterone, with associated high levels of INSL3, at 2 months postpartum that has been associated with the “extra” population of Leydig cells in the human (termed neonatal Leydig cells—see below) [9–



**Fig. 2.2** Pubertal adult human Leydig cells. This electron micrograph of a resin section shows part of two adult human Leydig cells. Lipid droplets (L) can be seen along with numerous mitochondria (example is indicated with an *arrowhead*) and abundant smooth endoplasmic reticulum. Reproduced from Prince [200] with permission from the publisher John Wiley and Sons

[11]. This post-natal testosterone surge is often referred to as “minipuberty” and may act to increase reproductive growth and alter neurobehavioral development in boys [12]. Beyond the neonatal period, Leydig cell numbers regress, although whether the fetal cells degenerate or remain in a morphologically unrecognized state is not clear. Either way, the interstitium contains few steroidogenically active cells during infancy [3]. The adult generation of Leydig cells starts to differentiate prepubertally but is not complete until adulthood [13] with serum levels of testosterone averaging 6 ng/ml (20 nmol/L) during adulthood [14]. Finally, there is a decline in testosterone secretion with aging, which is variable in its magnitude and time of onset. This age-related decline is multifactorial (see below), but it is likely to be associated with decreased testosterone production by the Leydig cells.


### Fetal Leydig Cells

The testes begin to develop in the human fetus at around 6 weeks of gestation, with migration of the preSertoli cells from the coelomic epithelium and formation of the sex cords [15]. Fetal Leydig cells can be identified in the interstitial compartment by about eight weeks of gestation [16]. Studies in the mouse indicate that the fetal Leydig cells originate

from two lineages: one arising from the coelomic epithelium and the other from cells associated with the vasculature along the gonad/mesonephros border [17]. Fetal Leydig cell numbers increase exponentially during the first half of the second trimester reaching a maximum number of about  $2 \times 10^6$  around 18 weeks [7] before declining again toward birth [7, 18]. Testosterone is first detectable in the testis as early as 6–7 weeks of gestation [19] and rises toward the prenatal peak at 12–14 weeks [7, 20]. This peak in testosterone is due to the increasing number of fetal Leydig cells and to increasing levels of chorionic gonadotrophin (hCG) [21] which acts through the LHCGR to stimulate Leydig cell function. Testosterone levels decline in the second half of gestation as hCG levels drop markedly and Leydig cell numbers decline [8, 20]. Surviving Leydig cells in the second half of gestation are partly dependent on pituitary LH [22] for activity.

### Neonatal Leydig Cells

Shortly after birth in the human, levels of LH rise and the number of Leydig cells increases leading to a neonatal surge in plasma testosterone levels at 2–3 months of age. At this stage, Leydig cells contain abundant smooth endoplasmic reticulum and mitochondria, as well as varying amounts of lipid droplets [13, 23, 24]. After the neonatal stage, Leydig cell numbers regress rapidly and become very scarce until six to eight years of age when they begin to increase toward adult levels. Well-differentiated Leydig cells are absent from the interstitial space during the quiescent phase, and in their place are partially differentiated Leydig cells and fibroblast-like cells. At this stage, Leydig cells are dispersed in a loose connective tissue matrix, and contain elongated nuclei with scarcely visible cytoplasm. It has been proposed that these partially differentiated Leydig cells and primitive fibroblasts are precursors of adult Leydig cells [25–27] although studies in the mouse would suggest other origins (see below). As suggested above, it has been proposed that the neonatal Leydig cells represent a third population of Leydig cells in the human, alongside the fetal



**Fig. 2.3** Steroidogenic pathways leading to formation of dihydrotestosterone (DHT). The canonical pathways through  $\Delta^4$  and  $\Delta^5$  steroids are shown on the left with the alternative (backdoor) pathway on the right. Enzymes shaded in gray are required for the canonical pathway (with a number also required for the alternative pathway). Enzymes shaded in yellow are specific to the alternative

pathway. Abbreviations; 5 $\alpha$ DHP, dihydropregesterone; 17OH-DHP, 17 $\alpha$ -hydroxydihydroprogesterone; DHEA dehydroepiandrosterone; DHT, dihydrotestosterone. This Figure was published in Knobil and Neill's Physiology of Reproduction, Vol 1, PJ O'Shaughnessy, Testicular Development, Pages 567–594, Copyright Elsevier (2015). Reprinted with permission

and adult populations [6]. Given that fetal Leydig cells persist in the mouse, however, a simpler explanation would be that this neonatal peak of testosterone is due to re-activation of the fetal Leydig cells by the increase in LH levels which occurs at this time [4].

### Adult Leydig Cells

The precursor cells for the adult Leydig cell population begin their transformation at 6–8 years of age, and the number of adult Leydig cells increases during puberty reaching a maximum reported as  $8 \times 10^8$  per testis in the young adult [13]. At this time, a third rise in testosterone concentrations occurs, and levels remain high into middle/old age. Thereafter, Leydig cell numbers may decline in men as they age past 60 years, but there is current uncertainty about this as discussed below (see Leydig cell aging). Either way, between ages 20 and 60, there is a relatively stable equilibrium in the number of Leydig cells, which make up about 4% of the volume of the mature testis [28].

### Steroidogenic Function of Leydig Cells

The main function of Leydig cells is to synthesize and secrete androgens, primarily testosterone. In humans, testosterone is synthesized mainly through the  $\Delta^5$  pathway via dehydroepiandrosterone (DHEA) and androstenedione (Fig. 2.3) [29]. This requires the activities of four enzymes: cholesterol side chain cleavage (CYP11A1), 17 $\alpha$ -hydroxylase/C<sub>17-20</sub> lyase (CYP17A1), 3 $\beta$ -hydroxysteroid dehydrogenase/ $\Delta^{5-4}$  isomerase (HSDB3), and 17 $\beta$ -hydroxysteroid dehydrogenase type 3 (HSD17B3) [30]. Leydig cells are the only cells in the testis which express CYP11A1, HSDB3, and CYP17A1 and are, therefore, the sole site for cholesterol conversion to C<sub>19</sub> steroids. In contrast, data from the mouse show that the HSD17B3 enzyme is expressed only in the Sertoli cells of the fetal/neonatal testis [31, 32] which means that fetal Leydig cells primarily secrete androstenedione (the  $\Delta^4$  pathway predominates in rodents) and Sertoli cells are required for testosterone synthesis. In the adult mouse, HSD17B3 is



expressed solely in the Leydig cells and the Leydig cells alone produce testosterone [31, 32]. Whether this pattern of HSD17B3 expression and steroid synthesis is specific to the mouse or is also relevant to the human remains to be determined. During fetal development, testosterone from the fetal Leydig cells will masculinize the internal ducts and glands but masculinization of the external genitalia depends on the formation of DHT in the genital tubercle [33]. Formation of DHT can be from testosterone through the action of SRD5A2, as shown in Fig. 2.3, but an alternative pathway has also been described which bypasses testosterone, and this pathway may be equally important for fetal masculinization in the human [34].

### Androgen Synthesis via the Canonical Pathway

Androgen synthesis from cholesterol depends initially upon the transport of cholesterol from intracellular sources to the inner mitochondrial membrane, and subsequent loading of cholesterol into the catalytic site of CYP11A1 [35]. Cholesterol is hydrophobic and cannot cross the aqueous intermembrane space of mitochondria to reach the CYP11A1 enzyme rapidly enough by simple diffusion to support acute steroid synthesis [36]. To overcome this problem, the cholesterol is transferred into the mitochondria through the transduceosome which includes the steroid acute regulator (STAR) protein, translocator protein, and voltage-dependent anion channel [37]. In the inner mitochondrial membrane, cholesterol is converted by CYP11A1 to pregnenolone and isocaproaldehyde [38] which is unstable and quickly oxidized to isocaproic acid. This reaction requires a mitochondrial electron transfer system of adrenodoxin and adrenodoxin reductase to convey electrons from NADPH to CYP11A1 [35].

Pregnenolone can act as substrate for testosterone synthesis through two different routes in the canonical pathway—the  $\Delta^4$  and  $\Delta^5$  pathways—so called because of the position of one of the double bonds on the steroid backbone. The particular

pathway taken is species-dependent and is regulated by the relative affinities of the converting enzymes for different substrates. In humans, the pathway is predominantly  $\Delta^5$  because CYP17A1 has a higher binding affinity for pregnenolone than HSD3B [39]. In rodents, CYP17A1 has a higher affinity for progesterone, and the  $\Delta^4$  pathway predominates [40]. In human Leydig cells, therefore, the pathway is predominantly through pregnenolone,  $17\alpha$ -hydroxypregnenolone, DHEA, androstenedione, and testosterone.

The enzymes involved in the canonical pathway are located in the mitochondria (CYP11A1, HSD3B2) and in the smooth endoplasmic reticulum (CYP17A1, HSD17B3) [30, 41]. In humans, there are two genes encoding HSD3B (types I and II) and both enzymes show the same activity although only HSD3B2 is expressed in the Leydig cells [42, 43]. The CYP17A1 enzyme carries out two steps in the bioconversion of pregnenolone and progesterone to the  $C_{19}$  steroids, DHEA, and androstenedione, respectively, with  $17\alpha$ -hydroxypregnenolone or  $17\alpha$ -hydroxyprogesterone as transient intermediates, although human CYP17A1 fails to show detectable activity with  $17\alpha$ -hydroxyprogesterone as substrate [40]. The final step in the formation of testosterone is the conversion of androstenedione to testosterone, catalyzed by HSD17B3. This enzyme is part of a family of 14 enzymes that show related activities [44], and in humans, HSD17B1 and HSD17B5 (a member of the aldo/keto reductase superfamily, also known as AKR1C3) are also able to carry out the same reaction [44]. It is clear, however, that in the human fetal testis at least, the HSD17B3 is predominant since XY individuals lacking functional HSD17B3 activity have a significantly reduced ratio of testosterone/androstenedione and fail to masculinize externally during fetal development [45]. Interestingly, testosterone levels rise at puberty in these individuals and virilization does occur leading to the suggestion that HSD17B5 may be of importance in the adult Leydig cells [46].

## Androgen Synthesis via the Alternative Pathway

Individuals who are genetic males but with disorders of activity in the enzymes of the canonical pathway will show disordered sex development (DSD) with incompletely masculinized external genitalia. Some cases of DSD (with normal androgen receptor signaling) cannot be explained by alterations in the canonical pathway, however, suggesting that other pathways/mechanisms are involved in androgen synthesis and masculinization [47]. In 2003, Wilson and colleagues described an alternative “backdoor” pathway of androgen synthesis in the testes of the pouch young tamar wallaby [48] (Fig. 2.3), and this pathway was subsequently shown to be active in the prepubertal mouse testis [49]. The importance of this pathway to human masculinization became apparent when unrelated individuals with DSD were shown to have disorders in one or more of the enzymes involved in the alternative pathway [34]. The non-functional/partially functional enzymes in these individuals were AKR1C4 and/or AKR1C2 which are both required for the alternative pathway but will not affect the canonical pathway (Fig. 2.3). Barring some other unknown mutation in these individuals, this would suggest that *both* canonical and alternative pathways to DHT synthesis are required during human male fetal development to ensure normal masculinization. Transcripts encoding enzymes involved in the alternative pathway have been shown to be present in the fetal human testis [34], and it has been assumed that testes secrete DHT via this pathway [34]. This is not clear, however, since earlier studies have reported little or no DHT synthesis by the human fetal testis [50, 51] suggesting that all DHT synthesis must take place at the target organ. It is also not clear whether the testes are the only organs involved in the alternative pathway since the fetal human liver also expresses at least some of the same enzymes [52]. Further studies are needed, therefore, to identify which tissues are involved in the alternative pathway,

and to measure the levels of the different pathway intermediates in the fetal circulation.

## Estrogen Synthesis by Human Leydig Cells

Estrogens are formed by aromatization of androstenedione or testosterone by the enzyme CYP19A1. In the testis of most species, aromatase activity is detectable in Leydig cells, Sertoli cells, and germ cells [53], and the relative contributions of each of these testicular cell types to testicular aromatase activity varies with age and between species. In the rat and mouse, Sertoli cells contribute to testicular aromatase activity in immature animals while germ cells are a significant site of activity in the adult [53]. Sertoli cells from juvenile Rhesus monkeys are reported to express aromatase activity, [54] although, in humans, Leydig cells appear to be the only source of testicular estrogens at all ages [55, 56].

## Androgen Secretion by the Leydig Cells/Testis

Once synthesized, the lipophilic androgens move out of the Leydig cells by passive diffusion, down the concentration gradient. Within the testis, testosterone and precursors diffuse freely into the interstitial space and enter the testicular blood capillaries that are immediately adjacent to Leydig cells [57]. Interestingly, it is this process of testosterone release into the testicular vascular bed which might be altered in Klinefelter syndrome leading to reduced circulating testosterone levels [58]. Once they are part of the systemic circulation, secreted testosterone binds to plasma proteins and is present in both bound and unbound forms. In adult humans, more than 95% of testosterone is complexed with proteins, both the high affinity ( $K_D = 1 \text{ nM}$ ) sex hormone binding globulin (SHBG) and the low affinity ( $K_D = 1000 \text{ nM}$ ) albumin. The proportion of testosterone that is unbound or loosely bound

represents the biologically active fraction, which freely diffuses from capillaries into cells. The SHBG-bound fraction is thought to act as a reservoir for the steroid, although SHBG-bound steroids may also enter cells via endocytic receptors on the surface of target cells and contribute to hormone action [58]. Increasing levels of SHBG during aging contributes to reduced free plasma testosterone during this period (see below, Leydig cell aging).

## Other Functions of the Leydig Cell

The principal function of the Leydig cells is to produce androgen, but the cells are also the only source of INSL3 during fetal development [59, 60]. This hormone is essential, along with androgen, for inducing normal testicular descent although INSL3-receptors (RXFP2) are found on Leydig cells and on germ cells, and there is evidence that INSL3 can act to reduce germ cell apoptosis [61]. Any role that INSL3 plays in Leydig cell function, however, is likely to be restricted to the period around early puberty [61]. In order to identify other functions of the Leydig cells, Leydig cell-specific transcripts in the adult rat have been identified on the assumption that at least some of these transcripts are likely to be involved in cell-specific functions [62, 63]. Apart from transcripts encoding components of the steroidogenic apparatus, the most common predicted function of translated proteins from these cell-specific transcripts is endogenous and xeno-toxicant metabolism and reduction in oxidative stress [62]. The Leydig cells may, therefore, play a significant role in protecting the adult testis from damage caused by toxicants or by stress.

---

## Regulation of Leydig Cell Development and Function

### Leydig Cell Development

Most information available on the control of Leydig cell development comes from rodent

models, and there is no reason to doubt that these fundamentals are significantly different in the human, but caution needs to be maintained when extrapolating between species.

Initial development of the fetal Leydig cells is dependent upon the Sertoli cells and, in particular, upon Desert Hedgehog (DHH) and Platelet-derived Growth Factor- $\alpha$  (PDGFA) released by the Sertoli cells [64–66]. In the absence of DHH in mice, there is a marked reduction in fetal Leydig cell numbers, reduced androgen levels and failure of masculinization, with a similar phenotype also seen in humans with a mutation in DHH [67, 68]. Similarly, reduced fetal Leydig cell numbers are seen in mice lacking PDGFA [69], and it is likely that the effect of both DHH and PDGFA is to promote expansion of the fetal Leydig cell precursor population [69]. In contrast, both NOTCH and WNT4 signaling act to inhibit fetal Leydig cell differentiation and WNT4 appears to be important in preventing Leydig cell development in the fetal ovary [70, 71]. Interestingly, downregulation of Wilm's tumor gene (WT1) may also be required for fetal Leydig cell development, with over-expression in fetal Leydig cells leading to development of a Sertoli cell-like phenotype [72, 73]. A number of homeoproteins (ARX, LHX9, PBX1, and RHOX4) are expressed in interstitial cells, and they have been shown to be involved in testis development. Only ARX has, so far, been linked directly to fetal Leydig cell development [74], however, possibly through an action on the progenitor cells [75]. In rodents, secretion of LH by the fetal pituitary is not required for fetal Leydig cell activity [76, 77], and once formed, the cells appear to function largely independently of the fetal Sertoli cells [78]. Similarly, fetal Leydig cell activity in humans is not dependent on fetal pituitary LH [79] but, unlike rodents, activation of the LHCGR is essential [80], indicating that hCG is required in humans to stimulate Leydig cell activity in utero [22].

The adult Leydig cells develop from peritubular precursors [81–83] which may be stem cells [84]. After initial differentiation, the cells undergo one or two mitotic divisions to reach the

final population size [85]. The initial process of adult Leydig cell differentiation is completely dependent on the Sertoli cells [78] since Sertoli cell ablation in the neonatal mouse leads to general failure of adult Leydig cell differentiation except in regions where Sertoli cells or Sertoli-like cells have survived ablation [78]. This failure of adult Leydig cell development is associated with apparent loss of Leydig cell precursor cells, although it is likely that the Sertoli cells are also directly involved in stimulating Leydig cell differentiation since DHH appears to be required for normal adult Leydig cell development, perhaps through inducing stem cell commitment [64, 86, 87]. The Sertoli cell-derived factor anti-Müllerian hormone (AMH) may also be involved in the regulation of adult Leydig cell development with a pubertal decrease in AMH required for normal maturation [88]. It has been shown that the orphan nuclear receptor NR2F2 is necessary for adult Leydig cell development, possibly through development of the progenitors and through maturation of the differentiated cells [89]. PDGFA is also involved in the differentiation process although the origin of this factor in the post-natal testis is not clear [90–93]. In addition to the requirement for Sertoli cells, it is clear that adult Leydig cell development is critically dependent on LH. Progenitor Leydig cells do not express the LH receptor [94], and initial Leydig cell differentiation is LH-independent [95, 96] but, in the absence of LH or the LH receptor, there is a marked reduction in the number of Leydig cells that develop in the adult [97]. Similarly, in mice with enhanced chronic exposure to LH activity, there is hyperplasia of the adult Leydig cell population [98]. Overall, therefore, the data suggest that initial Leydig cell differentiation is Sertoli cell-dependent/LH-independent, but that further development of the cells is critically dependent on LH.


One other factor of importance in Leydig cell development is androgen. In mice lacking androgen receptors, there is failure of normal adult Leydig cell development, with a reduction in Leydig cell number, and those cells which do develop lack many transcripts/proteins which are

associated with the adult cell population [99, 100]. In mice with a more specific deletion of androgen receptors only in the Leydig cell, there is also inhibition of cell maturation although the effect is less marked than with complete androgen receptor deletion [101]. Leydig cell numbers are unaffected in Leydig cell-specific knockouts and so androgen effects on Leydig cell development appear to be a mix of direct effects on the cells and indirect effects through other cells which express androgen receptors such as the peritubular myoid cells and Sertoli cells. In humans lacking functional androgen receptors, Leydig cell dysfunction appears to be less marked than in the mouse, with circulating testosterone levels in the normal range, albeit with high circulating LH levels [102–105]. This difference may be accounted for by loss of CYP17A1 in mice lacking androgen receptors [106], as the CYP17A1 enzyme levels appear to be normal, or possibly increased, in androgen-insensitive humans [107]. Interestingly, in both mouse and human, loss of androgen receptors leads to late-onset Leydig cell apoptosis, an event that is very rare in normal Leydig cell populations [101]. Androgenic stimulation also appears to be required by the adult Leydig cell stem cells during fetal life to ensure normal stem cell numbers in the adult [108] which may explain evidence suggesting that reduced fetal androgen exposure is associated with lower adult male androgen levels [109].

## Regulation of Leydig Cell Activity

The main regulator of Leydig cell activity is LH, and two types of responses to LH are seen. The first, acute response triggers a rapid production of steroid within minutes [110] through the binding of LH to the receptor, stimulation of adenylate cyclase, and the formation of the second messenger adenosine 3',5'-cyclic monophosphate (cAMP) (Fig. 2.4). Increased cAMP causes subsequent phosphorylation of proteins via protein kinase A or C [111, 112] in a cascade of events leading to increased STAR phosphorylation and expression and increased testosterone synthesis.





**Fig. 2.4** Mechanisms of hormone-mediated steroid production in Leydig cells. LH is the major endocrine regulator of Leydig cell steroidogenesis, and binding of LH to the LH receptor (LHR also termed LHCGR) leads to activation of adenylate cyclase (AC). Osteocalcin (Os) also activates adenylate cyclase through binding to GPCR6A. Activation of adenylate cyclase leads to an increase in cAMP which, in turn, causes influx of  $\text{Ca}^{2+}$  into the cells and induces activation of various kinases including protein kinase A (PKA). This leads to activation

of transcription factors (e.g. CREB, GATA4, NUR77) and induced expression of genes involved in steroid hormone synthesis, including STAR. Increased cAMP also activates the MAP kinase pathway via activation of the epidermal growth factors receptor (EGFR) which leads to increased expression and phosphorylation of STAR. The overall effect in the short term is to increase testosterone synthesis by the Leydig cells and, in the longer term, to increase transcription of the steroidogenic enzymes

The increase in cAMP also leads to the activation of a  $\text{Ca}^{2+}$ -signaling pathway [113] and increased NR4A1-mediated hormone-stimulated STAR expression [114]. In addition, LH-induced cAMP signaling in the Leydig cell transactivates the epidermal growth factor receptor (EGFR) leading to activation and expression of STAR protein [115] (Fig. 2.4). The second effect of LH is a long-term trophic effect on the Leydig cells mediated through transcriptional regulation. LH signaling acts through phosphorylation of transcription factors to enhance transcription from cyclic AMP-response elements (CREs) in the promoters for several LH target genes including STAR, CYP11A1, and HSD3B [110, 116]. Some target genes lack a consensus CRE, and expression is modulated by interaction between different transcription factors such as NR5A1 [117]. Overall, in the longer term, LH acts to maintain the steroidogenic enzyme activity of the Leydig

cell and the steroidogenic apparatus. This can be seen clearly in animals which lack LH stimulation either through gene mutation/manipulation or after treatment such as hypophysectomy. In *hpg* or *LHRKO* mice, which both lack LH stimulation; the Leydig cells are smaller and contain large lipid droplets; steroidogenic enzyme transcript level/activity is markedly reduced and androgen output in response to trophic stimulation is very low [95–97, 118].

In addition to LH, adrenocorticotrophic hormone (ACTH) can act to regulate fetal Leydig cell function in the mouse, although it does not appear to have any effect on adult Leydig cells [119]. Isolated fetal/neonatal mouse testes or Leydig cells will respond rapidly in vitro to physiological levels of ACTH with a marked rise in testosterone, similar to that seen in response to LH [119, 120]. It is not clear that ACTH plays a physiological role in development of the fetal

Leydig cells in mice, however, since androgen levels are normal in mice lacking ACTH or ACTH and LH [121]. It remains to be seen whether ACTH is of importance to fetal Leydig cell function in species, such as the human, which require trophic endocrine support for normal fetal androgen production. Responsiveness of fetal Leydig cells to ACTH in the mouse does raise one interesting aspect of these cells and that is their similarity to adrenocortical cells. It has been reported that at least some of the fetal Leydig cells may derive from the same progenitor population as the adrenocortical cells [122], and at least some of the cells show distinct similarities both in hormone responsiveness and steroidogenic enzyme expression [123–125]. Whether these are a subpopulation of normal fetal Leydig cells or ectopic adrenal cells which have been shown to give rise to adrenal rest tumors in the testis [126] remains to be seen.

In rodents, the fetal Leydig cells are also responsive to a variety of local and endocrine factors such as pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and natriuretic peptides [127–129]. Since fetal Leydig cells in rodents do not specifically require LH, it is possible that activation of the cells *in vivo* is through multiple redundant mechanisms involving LH, ACTH, and activating peptides. A redundant mechanism such as this may have evolved to ensure that sufficient Leydig cell activation occurs to induce fetal masculinization. Whether human fetal Leydig cells are also sensitive to multiple agonists is not known, although it is clear that human fetal androgen production is critically dependent on LHCG stimulation [80].

Recently, the bone protein osteocalcin has been reported to act as a trophic hormone on adult Leydig cells via the GPRC6A receptor [130, 131] (Fig. 2.4). Osteocalcin was shown to have a direct effect on testosterone synthesis by adult Leydig cells, and circulating testosterone levels and seminal vesicle weights were significantly reduced in mice lacking osteocalcin [130]. These effects were less marked than in mice lacking LH, but the fertility of the osteocalcin-deficient mice was reduced

indicating that osteocalcin is required for optimal reproductive function. Evidence from two human patients with primary testicular failure linked to mutations in GPRC6A is also supportive of the hypothesis that osteocalcin can regulate testicular function [131]. The link between steroid hormones and bone mass has been known for a number of years but these data show that the skeleton can regulate Leydig cell function in a classic endocrine feedback loop [132].


In addition to the direct effects of LH, ACTH, and osteocalcin on Leydig cell function, follicle stimulating hormone (FSH) may play an indirect stimulatory role in the regulation of Leydig cells. Evidence for an effect of FSH comes from gonadotrophin-deficient mice and rats treated with FSH, and from differences in Leydig cell function between control mice and animals lacking FSH stimulation [133–137]. In addition to mice, there is also evidence that FSH can stimulate Leydig cell function indirectly in other species including humans [18, 138–140]. FSH receptors are restricted to the Sertoli cells [141], and so FSH effects on the Leydig cells must be mediated through Sertoli-secreted factors. The effects of FSH are fairly rapid, however, with a response seen in *hpg* mice in less than 4 h [135] suggesting that whatever paracrine factors are involved they must be acting directly on the Leydig cells. These effects of FSH are consistent with recent studies which show that ablation of the Sertoli cells in the adult mouse causes a marked reduction in Leydig cell number within 30 days [142], demonstrating that Sertoli cell factors are required for maintenance of the adult Leydig cell population. The identity of these factors remains unknown but an obvious candidate is DHH which is closely involved in Leydig cell development and continues to be secreted specifically by the Sertoli cells into adulthood.

---

## Clinical Aspects

### Leydig Cell Aging

Most studies show that plasma levels of total testosterone in men fall between 1% and 2% per



**Fig. 2.5** Age-dependent changes in male hormone levels. These graphs show the relationship between age and hormone levels in men. Mean hormone values at 5-year age bands are shown based on data from 3220 men. Men with known pituitary or testicular diseases or current use of medications that could affect pituitary or testicular function or sex-steroid clearance were excluded. Total testosterone and free testosterone were significantly lower and luteinizing hormone (LH) and sex hormone binding globulin (SHBG) significantly higher in the older age groups. There was an apparent inflection point around 70 year for LH. Data shown in these figures are from [145] with permission of the authors

year beginning at about age 40, although free testosterone declines more rapidly ( $\sim 3\%$  per year) as levels of SHBG increase at the same time [143–145] (Fig. 2.5). This decline in testosterone is multifactorial but can be divided into primary/compensated hypogonadism (low/normal testosterone with high LH) which is primarily linked to aging and secondary hypogonadism (low testosterone with low LH) which does not appear to be age-related but is clearly linked to obesity [146]. Metabolic clearance of testosterone slows with age [147] (which would

tend to increase circulating testosterone), and so the increased LH seen in primary/compensated hypogonadism is evidence that the primary endocrine failure associated with aging is likely to be at the level of the testis [148]. Also, it has been shown that the circulating androgen response to increased LH declines with age in humans [148, 149] as might be expected from primary testicular failure.

Age-related declines in testicular testosterone output could be caused by decreased Leydig cell numbers and/or reduced steroidogenic ability. There are a number of studies which report that Leydig cell numbers decline with age in the human population [150–153], although a more recent study found no age-related change in Leydig cell number [154]. Counting cell numbers in the testis is prone to technical problems which may have affected the older studies while the number of men over 60 in the more recent report [154] was only 4, so whether Leydig cell number declines with aging will remain uncertain until further studies are carried out.

Whether or not Leydig cell numbers decline with age, there is good evidence for degenerative changes in the cells including cytoplasmic or intranuclear crystalline inclusions, lipofuscin granules, diminished smooth endoplasmic reticulum, and smaller and fewer mitochondria when compared to young men [155–157]. Older men with higher serum LH and lower serum testosterone levels also have a large number of abnormal Leydig cells, suggesting that Leydig cell structural changes are related to changes in steroidogenic function [155]. Studies of intratesticular steroid levels in aging men do not show a specific lesion in the steroidogenic pathway but overall levels are lower, and there is evidence of reduced mitochondrial steroid production [158]. Using rat models in which the primary aging deficit is at the level of the Leydig cells, it has been shown that Leydig cell aging in the rat is associated with multiple defects in the steroidogenic machinery from reduced LH-dependent cAMP production to reduced steroidogenic enzyme levels [159]. This deterioration of Leydig

cell function may be related to alterations in the redox balance of the cells leading to increased superoxide content with aging [159]. It is also likely, however, that other factors also contribute to the decline in Leydig cell function with age, as newly formed Leydig cells in testes from aged Norway rats show a rapid decline in steroidogenic function [160]. This does not appear to be due to changes in LH but may be caused by alterations in the levels of other trophic factors, changes in cell–cell signaling in the testis or vascular re-modeling associated with aging.

### Leydig Cell Tumors


Leydig cell tumors were first identified by Sacchi in 1895, and are the most common interstitial tumors although they are rare overall and account for only 1–3% of testicular tumors [161–163]. Most Leydig cell tumors are unilateral (only 3% are bilateral [164]) and can appear at any age, although there is a peak incidence before puberty (between 5 and 10 years) and a second larger peak between 30 and 60 years. The tumors produce androgens, mainly testosterone, but serum estrogen levels may be elevated either through direct production of estrogen by the tumor or by peripheral aromatization of secreted androgen [165]. In boys, Leydig cell tumors are uniformly benign, hormonally active tumors, and account for about 10% of cases of precocious puberty [166]. In adults, most Leydig cell tumors are benign, and patients present with a painless testicular mass which may be palpable but is usually an incidental finding on scrotal ultrasonography for other conditions [167]. Small non-palpable Leydig cell tumors which are not visible on ultrasonograms can be seen by magnetic resonance imaging [168]. Where there is significant estrogen production, gynecomastia may be present along with loss of libido, erectile dysfunction, impotence, and infertility [165]. In adults, approximately 10% of Leydig cell tumors are malignant [162, 163] with regional lymph nodes, liver, lungs, and bone, the most common sites of metastases [162].

Macroscopically, the lesions associated with Leydig cell tumors are generally small, yellow to brown, well circumscribed and rarely hemorrhagic or necrotic. Microscopically, four different cell types can be found, ranging from large polygonal cells to spindle-shaped sarcomatoid cells [165, 169]. The cells have round nuclei with eosinophilic granular cytoplasm containing lipid vacuoles, lipofuscin granules, and Reinke's crystals present in about one third of the cases [170] (Fig. 2.6). Ultrastructurally, the cells show features expected of steroid-secreting cells, including abundant smooth endoplasmic reticulum.

Classically, the primary treatment for Leydig cell tumors has been radical orchiectomy, and it remains in use for malignant cases. Testis-sparing surgery, with enucleation of the mass, has proved to be a feasible and safe choice, however, and is increasingly being reported for benign cases. A recent study of patients with Leydig cell tumors found a 100% disease-free survival with no local recurrences or metastases following testis-sparing surgery [171]. Testis-sparing surgery should also be considered for children who present with the clinical and biochemical findings typical of Leydig cell tumors, and an ultrasonographically defined encapsulated intratesticular mass [172]. Malignant Leydig cell tumors are radio-resistant and chemo-resistant, and have a poor prognosis with median survival time of 2 years [173].

The etiology of Leydig cell tumors remains uncertain, particularly in adults, but somatic activating mutations of the LHCGR have been found in a number of these tumors in boys [174]. This is consistent with the gonadotropin-independent nature of these tumors and with the development of fetal Leydig cell tumors in mice exposed to persistently high levels of hCG [175]. Other somatic mutations are also likely to be involved although a link to activating mutations in genes such as the Gs  $\alpha$ -subunit of the stimulatory G protein (GNAS) have not been shown [174]. Leydig cell tumors in adults may be derived from the adult population of Leydig cells which would be consistent with the presence of Reinke's crystals in some tumors as fetal Leydig cells lack these structures [176]. This





**Fig. 2.6** Leydig cell tumors. Histologic sections of Leydig cell tumors. **a** Leydig cell tumor cells have abundant, eosinophilic cytoplasm with regular round nuclei, distinct cell borders and fibrovascular septa between the tumor cells. **b** Periodic acid Schiff stain which highlights the cytoplasmic lipofuscin granules in the tumor cells, a diagnostic clue to Leydig cell tumors. **c** Higher power photomicrograph showing intracytoplasmic Reinke crystals in a Leydig cell tumor (*arrows*). The crystals appear as refractile, cylindrical, rectangular, or rhomboid structures, and their identification is helpful for distinguishing Leydig cell tumors from other similar

lesions (hematoxylin-eosin). **d** Leydig cell tumors typically show strong, diffuse cytoplasmic reactivity for  $\alpha$ -inhibin (INHA) which is shown here as a brown stain. INHA is a sensitive and specific marker that can be used to separate testicular sex cord–stromal tumors, including Leydig cell tumors, from germ cell tumors, Reprinted from Al-Agha & Axiotis, *An In-Depth Look at Leydig Cell Tumor of the Testis*. Arch Pathol Lab Med. 2007; Vol 131 (issue 2): pp 311–317 with permission from Archives of Pathology & Laboratory Medicine. Copyright 2007 College of American Pathologists [165]

may mean that the etiology of adult tumors differs from tumors in boys. The tyrosine kinase inhibitor imatinib has been reported to show chemotherapeutic activity in animal models [177], but this activity has not been demonstrated in an adult human trial [178].

Leydig cell hyperplasia shares the same clinical presentation as a Leydig cell tumor, including painful gynecomastia and decreased libido in adults, precocious puberty in children, and infertility or palpable testicular masses [179]. It should be noted, however, that many cases of

apparent Leydig cell hyperplasia reported in the literature, in both humans and rodent models, are due to loss of germ cells (e.g., through cryptorchidism) causing shrinkage of the seminiferous tubules and an apparent increase in relative interstitial volume. Stereological measurement of Leydig cell numbers in these cases will often show no change in Leydig cell number per testis [180]. It is significant, therefore, that reported clinical Leydig cell hyperplasia is always associated with spermatogenic failure [179]. However, there is no doubt that true Leydig cell



hyperplasia can occur if LH (or hCG) levels are elevated [179], and the hyperplastic Leydig cells are generally arranged in diffuse, multifocal, small nodules and show frequent mitoses, necrosis, and vascular invasion. Hyperplastic Leydig cells usually infiltrate between seminiferous tubules while benign Leydig cell tumors form nodules that compress surrounding tubules.

### Leydig Cell Toxicology

As described above, the Leydig cells express a number of metabolic enzymes which might be expected to inactivate xenotoxins and thereby protect the spermatogenic and steroidogenic function of the testis [62]. At the same time, however, the Leydig cells themselves are the potential target of a number of possible toxicants. This is an area which has seen a marked increase in publication activity in the last 10 years, with a considerable number of potential toxicants identified, and some of the better characterized/most relevant substances include phthalates, bisphenol A, statins, and ethanol. Phthalates are present in food packaging, cosmetics, and medical devices such as tubings and catheters, and so human exposure is significant with particular concern about fetal exposure [181]. Inhibitory effects of phthalates on rodent Leydig cell development and function are well documented, particularly with respect to the fetal Leydig cells, and may be related to altered expression of NR2F2 [182]. Changes to fetal Leydig cell development would be likely to affect normal masculinization of the fetus and are, therefore, potentially serious, but the effects of phthalates may be species-dependent with no clear effect seen in human fetal testis organ culture [181, 183], although there may be effects on adult human Leydig cells [184]. Bisphenol A is ubiquitous in the environment and is used primarily to manufacture polycarbonate plastic or as a non-polymer additive to other plastics and to epoxy resins. Bisphenol A has estrogenic activity and is classed as an endocrine disrupting compound, but it is also reported to directly inhibit fetal Leydig cell function in both rats and humans [185, 186]

and is of ongoing concern. Statins act to inhibit cholesterol synthesis, and are taken daily by an estimated 20 million men, many of whom are more than 60 years old, and so with aging Leydig cells. Leydig cells need cholesterol as substrate for androgen synthesis (Fig. 2.3), some of which comes from circulating lipoproteins and some from *de novo* synthesis. A recent meta-analysis reported that statins reduce circulating testosterone concentration in men [187] which would be consistent with reported inhibitory effects in vitro on rat Leydig cells [188, 189], although no studies have yet been reported using isolated human Leydig cells. Long-term abuse of ethanol reduces circulating testosterone levels which may be a combination of direct effects on the Leydig cells [190, 191] with changes in circulating LH. Most studies report normal or elevated LH following alcohol abuse but the gonadotrophin response to pituitary stimulation is reduced suggesting altered hypothalamic pituitary function [190, 192, 193]. Finally, it has been shown that the alkylating agent ethane dimethane sulfonate (EDS) can act as a specific cytotoxicant in Leydig cells. This effect is species-specific with complete Leydig cell ablation seen in rats within 24 h but with little effect seen in the mouse, dog, and monkey [194]. It is still not known why the cytotoxic effect is specific to Leydig cells in the rat, but EDS has proven particularly useful in the study of Leydig cell biology [194].

---

### Conclusions—Future Work

The importance of testosterone to adult male health is increasingly recognized, with an established link now made between low testosterone and the onset of conditions such as obesity, metabolic syndrome, and type 2 diabetes [1, 195–197]. It is clear, therefore, that we need to understand how Leydig cells are regulated in the adult human, and why testosterone levels are low in some individuals. In general, our knowledge and understanding of testis biology and Leydig cell function are expanding quickly due largely to the availability of transgenic mouse models which allow hormonal control and cell–cell

interactions to be dissected and examined. With the important exception of fetal development, specific studies on the human Leydig cell are limited, however, and it is clear that more human-specific information is needed, particularly for important areas such as Leydig cell aging and toxicology. There has been increased availability of human fetal tissues for research in recent years which means that our understanding of this phase of human testicular development is improving, although use of human fetal material remains controversial in the USA (<http://tinyurl.com/hrxj29r>). It is known that fetal programming can have a marked effect on adult health [198], and there is evidence that low testosterone in the fetus is associated with reduced adult testosterone levels [109, 199] perhaps through changes in Leydig stem cell development [108]. The recent identification of factors which appear to be required for Leydig stem cell differentiation in the rat [87] highlights an area which is likely to be of considerable focus in coming years as interest develops in the manipulation of this process.

**Acknowledgements** Support from the BBSRC (BB/J015105) and MRC (MR/L01001) during the preparation of this manuscript is acknowledged.

## References

1. Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. *Rev Endocr Metab Disord.* 2015;16:249–68. doi:10.1007/s11154-015-9323-2.
2. Christensen A. A history of Leydig cell research. In: Payne AH, Hardy MP, editors. *The Leydig cell in health and disease*. Totowa: Humana Press; 2007. p. 3–30.
3. Teerds KJ, Huhtaniemi IT Morphological and functional maturation of Leydig cells: from rodent models to primates. *Hum Reprod Update* 2015;21: 310–28. doi:10.1093/humupd/dmv008 dmv008 [pii].
4. Shima Y, Matsuzaki S, Miyabayashi K, Otake H, Baba T, Kato S, Huhtaniemi I, Morohashi K. Fetal Leydig cells persist as an androgen-independent subpopulation in the postnatal testis. *Mol Endocrinol.* 2015;29:1581–93. doi:10.1210/me.2015-1200.
5. Forest MG, De Peretti E, Bertrand J. Hypothalamic-pituitarygonadal relationships in man from birth to puberty. *Clin Endocrinol (Oxf).* 1976;5:551–69.
6. Prince FP. The triphasic nature of Leydig cell development in humans, and comments on nomenclature. *J Endocrinol.* 2001;168:213–6.
7. O'Shaughnessy PJ, Baker PJ, Monteiro A, Cassie S, Bhattacharya S, Fowler PA. Developmental changes in human fetal testicular cell numbers and messenger ribonucleic acid levels during the second trimester. *J Clin Endocrinol Metab.* 2007;92: 4792–801.
8. Fowler PA, Bhattacharya S, Gromoll J, Monteiro A, O'Shaughnessy PJ. Maternal smoking and developmental changes in luteinizing hormone (LH) and the LH receptor in the fetal testis. *J Clin Endocrinol Metab.* 2009;94:4688–95.
9. Winter JS, Hughes IA, Reyes FI, Faiman C. Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal steroid concentrations in man from birth to two years of age. *J Clin Endocrinol Metab.* 1976;42:679–86.
10. Winter JS, Faiman C, Hobson WC, Prasad AV, Reyes FI. Pituitary-gonadal relations in infancy. I. Patterns of serum gonadotropin concentrations from birth to four years of age in man and chimpanzee. *J Clin Endocrinol Metab.* 1975;40:545–51.
11. Bay K, Virtanen HE, Hartung S, Ivell R, Main KM, Skakkebaek NE, Andersson AM, Toppari J Insulin-like factor 3 levels in cord blood and serum from children: effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. *J Clin Endocrinol Metab* 2007;92:4020–027. doi:10.1210/jc.2007-0974 jc.2007-0974 [pii].
12. Kuiri-Hanninen T, Sankilampi U, Dunkel L Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. *Horm Res Paediatr* 2014;82: 73–80. doi:10.1159/000362414 000362414 [pii].
13. Nistal M, Paniagua R, Regadera J, Santamaria L, Amat P. A quantitative morphological study of human Leydig-cells from birth to adulthood. *Cell Tissue Res.* 1986;246:229–36.
14. Carlstrom K, Eriksson A, Stege R, Rannevik G. Relationship between serum testosterone and sex hormone-binding globulin in adult men with intact or absent gonadal function. *Int J Androl.* 1990;13:67–73.
15. Gondos B. Development and differentiation of the testis and male reproductive tract. In: Steinberger A, Steinberger B, editors. *Testicular development, structure and function*. New York: Raven Press; 1980. p. 3–20.
16. Voutilainen R. Differentiation of the fetal gonad. *Horm Res.* 1992;38(Suppl 2):66–71.
17. DeFalco T, Takahashi S, Capel B Two distinct origins for Leydig cell progenitors in the fetal testis. *Dev Biol* 2011;352:14–26. doi:10.1016/j.ydbio.2011.01.011 S0012-1606(11)00027-3 [pii].
18. O'Shaughnessy PJ. Testicular development. In: Plant Tony, Zeleznik Anthony, editors. *Knobil*

- and Neill's physiology of reproduction. Amsterdam: Academic Press; 2015. p. 567–94.
19. Tapanainen J, Kellokumpulehtinen P, Pelliniemi L, Huhtaniemi I. Age-related-changes in endogenous steroids of human-fetal testis during early and mid-pregnancy. *J Clin Endocrinol Metab*. 1981;52:98–102.
  20. Clements JA, Reyes FI, Winter JS, Faiman C. Studies on human sexual development. III. Fetal pituitary and serum, and amniotic fluid concentrations of LH, CG, and FSH. *J Clin Endocrinol Metab*. 1976;42:9–19.
  21. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro- $\alpha$  C and follistatin during pregnancy. *Hum Reprod*. 1998;13:3530–6.
  22. O'Shaughnessy P, Fowler PA. Endocrinology of the mammalian fetal testis. *Reproduction*. 2011;141:37–46.
  23. Huhtaniemi I, Pelliniemi LJ. Fetal Leydig cells: cellular origin, morphology, life span, and special functional features. *Proc Soc Exp Biol Med*. 1992;201:125–40.
  24. Pelliniemi LJ, Niei M. Fine structure of the human foetal testis. I. The interstitial tissue. *Z Zellforsch Mikrosk Anat*. 1969;99:507–22.
  25. Chemes H, Cigorraga S, Bergada C, Schteingart H, Rey R, Pellizzari E. Isolation of human leydig-cell mesenchymal precursors from patients with the androgen insensitivity syndrome—testosterone production and response to human chorionic-gonadotropin stimulation in culture. *Biol Reprod*. 1992;46:793–801.
  26. Prince FP. Ultrastructure of immature leydig-cells in the human prepubertal testis. *Anat Rec*. 1984;209:165–76.
  27. Chemes HE, Gottlieb SE, Pasqualini T, Domenichini E, Rivarola MA, Bergada C. Response to acute hCG stimulation and steroidogenic potential of Leydig cell fibroblastic precursors in humans. *J Androl*. 1985;6:102–12.
  28. de Kretser D, Kerr JB. The cytology of the testis. In: Ernst K, Neil JD, editors. *The physiology of reproduction*. New York: Raven Press; 1994. p. 1177–290.
  29. Luu-The V. Assessment of steroidogenesis and steroidogenic enzyme functions. *J Steroid Biochem Mol Biol* 2013;137:176–82. doi:[10.1016/j.jsbmb.2013.05.017](https://doi.org/10.1016/j.jsbmb.2013.05.017) S0960-0760(13)00112-X [pii].
  30. Payne AH, O'Shaughnessy PJ. Structure, function and regulation of steroidogenic enzymes in the Leydig cell. In: Payne AH, Hardy MP, Russell LD, editors. *The Leydig cell*. Vienna, USA: Cache River Press; 1996. p. 259–85.
  31. Shima Y, Miyabayashi K, Haraguchi S, Arakawa T, Otake H, Baba T, Matsuzaki S, Shishido Y, Akiyama H, Tachibana T, Tsutsui K, Morohashi KI. Contribution of Leydig and Sertoli Cells to testosterone production in mouse fetal testes. *Mol Endocrinol* 2012;27:63–73. doi:[10.1210/me.2012-1256](https://doi.org/10.1210/me.2012-1256)me.2012-1256 [pii].
  32. O'Shaughnessy PJ, Baker PJ, Heikkila M, Vainio S, McMahon AP. Localization of 17 $\beta$ -hydroxysteroid dehydrogenase/17-ketosteroid reductase isoform expression in the developing mouse testis— androstenedione is the major androgen secreted by fetal/neonatal leydig cells. *Endocrinology*. 2000;141:2631–7.
  33. Wilson JD, George FW, Griffin JE. The hormonal-control of sexual development. *Science*. 1981;211:1278–84.
  34. Fluck CE, Meyer-Boni M, Pandey AV, Kempna P, Miller WL, Schoenle EJ, Biason-Lauber A. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. *Am J Hum Genet* 2011;89:201–18. doi:[10.1016/j.ajhg.2011.06.009](https://doi.org/10.1016/j.ajhg.2011.06.009) S0002-9297(11)00262-X [pii].
  35. Papadopoulos V, Miller WL. Role of mitochondria in steroidogenesis. *Best Pract Res Clin Endocrinol Metab* 2012;26:771–90. doi:[10.1016/j.beem.2012.05.002](https://doi.org/10.1016/j.beem.2012.05.002) S1521-690X(12)00063-2 [pii].
  36. Stocco DM, Clark BJ. Regulation of the acute production of steroids in steroidogenic cells. *Endocr Rev*. 1996;17:221–44.
  37. Papadopoulos V, Aghazadeh Y, Fan J, Campioli E, Zirkin B, Midzak A. Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis. *Mol Cell Endocrinol* 2015;408:90–8. doi:[10.1016/j.mce.2015.03.014](https://doi.org/10.1016/j.mce.2015.03.014) S0303-7207(15)00145-8 [pii].
  38. Burstein S, Gut M. Intermediates in the conversion of cholesterol to pregnenolone: kinetics and mechanism. *Steroids* 1976;28:115–31. 0039-128X(76)90131-8 [pii].
  39. Biason-Lauber A, Miller WL, Pandey AV, Fluck CE of marsupials and men: “Backdoor” dihydrotestosterone synthesis in male sexual differentiation. *Mol Cell Endocrinol* 2013;371:124–32. doi:[10.1016/j.mce.2013.01.017](https://doi.org/10.1016/j.mce.2013.01.017) S0303-7207(13)00040-3 [pii].
  40. Brock BJ, Waterman MR. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. *Biochemistry*. 1999;38:1598–606. doi:[10.1021/bi9821059](https://doi.org/10.1021/bi9821059) [doi];bi9821059 [pii].
  41. Thomas JL, Bose HS. Regulation of human 3- $\beta$ -hydroxysteroid dehydrogenase type-2 (3- $\beta$ HSD2) by molecular chaperones and the mitochondrial environment affects steroidogenesis. *J Steroid Biochem Mol Biol* 2015;151:74–84. doi:[10.1016/j.jsbmb.2014.11.018](https://doi.org/10.1016/j.jsbmb.2014.11.018) S0960-0760(14)00283-0 [pii].
  42. Dupont E, Zhao HF, Rheaume E, Simard J, Luuthe V, Labrie F, Pelletier G. Localization of 3 $\beta$ -hydroxysteroid dehydrogenase D5-D4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization. *Endocrinology*. 1990;127:1394–403.

43. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH Molecular biology of the 3 $\beta$ -hydroxysteroid dehydrogenase/ $\Delta$ 5- $\Delta$ 4 isomerase gene family. *Endocr Rev*. 2005.
44. Saloniemi T, Jokela H, Strauss L, Pakarinen P, Poutanen M The diversity of sex steroid action: novel functions of hydroxysteroid (17 $\beta$ ) dehydrogenases as revealed by genetically modified mouse models. *J Endocrinol* 2012;212:27–40. doi:[10.1530/JOE-11-0315](https://doi.org/10.1530/JOE-11-0315) JOE-11-0315 [pii].
45. Boehmer AL, Brinkmann AO, Sandkuijl LA, Halley DJ, Niermeijer MF, Andersson S, de Jong FH, Kayserili H, de Vroede MA, Otten BJ, Rouwe CW, Mendonca BB, Rodrigues C, Bode HH, de Ruiter PE, Delemarre-van de Waal HA, Drop SL. 17 $\beta$ -hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. *J Clin Endocrinol Metab*. 1999;84:4713–21. doi:[10.1210/jcem.84.12.6174](https://doi.org/10.1210/jcem.84.12.6174).
46. Werner R, Kulle A, Sommerfeld I, Riepe FG, Wudy S, Hartmann MF, Merz H, Dohnert U, Bertelloni S, Holterhus PM, Hiort O Testosterone synthesis in patients with 17 $\beta$ -hydroxysteroid dehydrogenase 3 deficiency. *Sex Dev* 2012;6:161–68. doi:[10.1159/000336605](https://doi.org/10.1159/000336605) 000336605 [pii].
47. Mendonca BB, Arnhold IJP, Domenice S, Costa EMF 46,XY Disorders of Sexual Development. NBK279170 2000 [bookaccession].
48. Wilson JD, Auchus RJ, Leiwy MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G, Renfree MB. 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol is formed in tammar wallaby pouch young testes by a pathway involving 5 $\alpha$ -pregnane-3 $\alpha$ ,17 $\alpha$ -diol-20-one as a key intermediate. *Endocrinology*. 2003;144:575–80.
49. Mahendroo M, Wilson JD, Richardson JA, Auchus RJ. Steroid 5 $\alpha$ -reductase 1 promotes 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol synthesis in immature mouse testes by two pathways. *Mol Cell Endocrinol*. 2004;222:113–20. doi:[10.1016/j.mce.2004.04.009](https://doi.org/10.1016/j.mce.2004.04.009).
50. Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual differentiation in the human embryo. *J Clin Endocrinol Metab*. 1974;38:113–25. doi:[10.1210/jcem-38-1-113](https://doi.org/10.1210/jcem-38-1-113).
51. George FW, Carr BR, Noble JF, Wilson JD. 5- $\alpha$ -reduced androgens in the human-fetal testis. *J Clin Endocrinol Metab*. 1987;64:628–30.
52. O'Shaughnessy PJ, Monteiro A, Bhattacharya S, Fraser MJ, Fowler PA Steroidogenic enzyme expression in the human fetal liver and potential role in the endocrinology of pregnancy. *Mol Hum Reprod* 2013;19:177–87. doi:[10.1093/molehr/gas059](https://doi.org/10.1093/molehr/gas059) gas059 [pii].
53. Carreau S, Bouraima-Lelong H, Delalande C Estrogen, a female hormone involved in spermatogenesis. *Adv Med Sci* 2012;57: 31–6. doi:[10.2478/v10039-012-0005-y](https://doi.org/10.2478/v10039-012-0005-y) D8734766262701R4 [pii].
54. Majumdar SS, Winters SJ, Plant TM. Procedures for the isolation and culture of Sertoli cells from the testes of infant, juvenile, and adult rhesus monkeys (*Macaca mulatta*). *Biol Reprod*. 1998;58:633–40.
55. Inkster S, Yue W, Brodie A. Human testicular aromatase: immunocytochemical and biochemical studies. *J Clin Endocrinol Metab*. 1995;80:1941–7. doi:[10.1210/jcem.80.6.7539819](https://doi.org/10.1210/jcem.80.6.7539819).
56. Carreau S. Leydig cell aromatase. In: Payne AH, Hardy MP, editors. *The Leydig cell in health and disease*. Totowa: Humana; 2007. p. 189–95.
57. Winters SJ, Takahashi J, Troen P. Secretion of testosterone and its delta4 precursor steroids into spermatic vein blood in men with varicocele-associated infertility. *J Clin Endocrinol Metab*. 1999;84:997–1001. doi:[10.1210/jcem.84.3.5548](https://doi.org/10.1210/jcem.84.3.5548).
58. Tuttmann F, Damm OS, Luetjens CM, Baldi M, Zitzmann M, Kliesch S, Nieschlag E, Gromoll J, Wistuba J, Simoni M. Intratesticular testosterone is increased in men with Klinefelter syndrome and may not be released into the bloodstream owing to altered testicular vascularization—a preliminary report. *Andrology*. 2014;2:275–81. doi:[10.1111/j.2047-2927.2014.00190.x](https://doi.org/10.1111/j.2047-2927.2014.00190.x).
59. Virtanen HE, Toppari J. Embryology and physiology of testicular development and descent. *Pediatr Endocrinol Rev*. 2014;11(Suppl 2):206–13.
60. Bay K, Cohen AS, Jorgensen FS, Jorgensen C, Lind AM, Skakkebaek NE, Andersson AM. Insulin-like factor 3 levels in second-trimester amniotic fluid. *J Clin Endocrinol Metab*. 2008;93:4048–51.
61. Ivell R, Heng K, Anand-Ivell R. Insulin-Like Factor 3 and the HPG Axis in the Male. *Front Endocrinol (Lausanne)*. 2014;5:6. doi:[10.3389/fendo.2014.00006](https://doi.org/10.3389/fendo.2014.00006).
62. O'Shaughnessy PJ, Monteiro A, Fowler PA, Morris ID Identification of Leydig cell-specific mRNA transcripts in the adult rat testis. *Reproduction* 2014;147:671–82. doi:[10.1530/REP-13-0603](https://doi.org/10.1530/REP-13-0603) REP-13-0603 [pii].
63. Zhang YF, Yuan KM, Liang Y, Chu YH, Lian QQ, Ge YF, Zhen W, Sottas CM, Su ZJ, Ge RS Alterations of gene profiles in Leydig-cell-regenerating adult rat testis after ethane dimethane sulfonate-treatment. *Asian J Androl* 2015;17:253–60. doi:[10.4103/1008-682X.136447](https://doi.org/10.4103/1008-682X.136447) 136447 [pii].
64. Clark AM, Garland KK, Russell LD. Desert hedgehog (Dhh) gene is required in the mouse testis for formation of adult-type Leydig cells and normal development of peritubular cells and seminiferous tubules. *Biol Reprod*. 2000;63:1825–38.
65. Pierucci-Alves F, Clark AM, Russell LD. A developmental study of the desert hedgehog-null mouse testis. *Biol Reprod*. 2001;65:1392–402.
66. Yao HH, Whoriskey W, Capel B. Desert Hedgehog/Patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. *Genes Dev*. 2002;16:1433–40.
67. Umehara F, Tate G, Itoh K, Yamaguchi N, Douchi T, Mitsuya T, Osame M A novel mutation of desert hedgehog in a patient with 46,XY partial gonadal dysgenesis accompanied by minifascicular

- neuropathy. *Am J Hum Genet* 2000;67:1302–305. doi:[10.1016/S0002-9297\(07\)62958-9](https://doi.org/10.1016/S0002-9297(07)62958-9) S0002-9297(07)62958-9 [pii].
68. Canto P, Soderlund D, Reyes E, Mendez JP. Mutations in the desert hedgehog (DHH) gene in patients with 46, XY complete pure gonadal dysgenesis. *J Clin Endocrinol Metab*. 2004;89:4480–3.
  69. Brennan J, Tilmann C, Capel B. Pdgfr- $\alpha$  mediates testis cord organization and fetal Leydig cell development in the XY gonad. *Genes Dev*. 2003;17:800–10.
  70. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. *Nature*. 1999;397:405–9.
  71. Tang H, Brennan J, Karl J, Hamada Y, Raetzman L, Capel B. Notch signaling maintains Leydig progenitor cells in the mouse testis. *Development* 2008;135: 3745–753. doi:[10.1242/dev.024786](https://doi.org/10.1242/dev.024786) dev.024786 [pii].
  72. Wen Q, Zheng QS, Li XX, Hu ZY, Gao F, Cheng CY, Liu YX. Wt1 dictates the fate of fetal and adult Leydig cells during development in the mouse testis. *Am J Physiol Endocrinol Metab* 2014;307:E1131–143. doi:[10.1152/ajpendo.00425.2014](https://doi.org/10.1152/ajpendo.00425.2014) ajpendo.00425.2014 [pii].
  73. Zhang L, Chen M, Wen Q, Li Y, Wang Y, Wang Y, Qin Y, Cui X, Yang L, Huff V, Gao F. Reprogramming of Sertoli cells to fetal-like Leydig cells by Wt1 ablation. *Proc Natl Acad Sci U S A* 2015;112:4003–008. doi:[10.1073/pnas.1422371112](https://doi.org/10.1073/pnas.1422371112) 1422371112 [pii].
  74. Kitamura K, Yanazawa M, Sugiyama N, Miura H, Iizuka-Kogo A, Kusaka M, Omichi K, Suzuki R, Kato-Fukui Y, Kamiirisa K, Matsuo M, Kamijo S, Kasahara M, Yoshioka H, Ogata T, Fukuda T, Kondo I, Kato M, Dobyns WB, Yokoyama M, Morohashi K. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. *Nat Genet*. 2002;32:359–69.
  75. Miyabayashi K, Katoh-Fukui Y, Ogawa H, Baba T, Shima Y, Sugiyama N, Kitamura K, Morohashi K. Aristaless related homeobox gene, Arx, is implicated in mouse fetal Leydig cell differentiation possibly through expressing in the progenitor cells. *PLoS ONE*. 2013;8:e68050. doi:[10.1371/journal.pone.0068050](https://doi.org/10.1371/journal.pone.0068050) PONE-D-13-03678 [pii].
  76. O'Shaughnessy PJ, Baker P, Sohnius U, Haavisto A-M, Charlton HM, Huhtaniemi I. Fetal development of Leydig cell activity in the mouse is independent of pituitary gonadotroph function. *Endocrinology*. 1998;139:1141–6.
  77. Zhang F-P, Poutanen M, Wilbertz J, Huhtaniemi I. Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. *Mol Endocrinol*. 2001;15:172–83.
  78. Rebourcet D, O'Shaughnessy PJ, Pitetti JL, Monteiro A, O'Hara L, Milne L, Tsai YT, Cruickshanks L, Riethmacher D, Guillou F, Mitchell RT, van't Hof R, Freeman TC, Nef S, Smith LB. Sertoli cells control peritubular myoid cell fate and support adult Leydig cell development in the prepubertal testis. *Development* 2014;141:2139–149. doi:[10.1242/dev.107029](https://doi.org/10.1242/dev.107029) 141/10/2139 [pii].
  79. Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL. Hypogonadism caused by a single amino acid substitution in the b-subunit of luteinizing hormone. *N Eng J Med*. 1992;326: 179–83.
  80. Kremer H, Kraaij R, Toledo SPA, Post M, Fridman JB, Hayashida CY, van Reen M, Milgrom E, Ropers HH, Mariman E, Themmen APN, Brunner HG. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. *Nat Genet*. 1995;9:160–4.
  81. Ariyaratne HB, Mendis-Handagama SM, Hales DB, Mason JI. Studies of the onset of Leydig precursor cell differentiation in the prepubertal rat testis. *Biol Reprod*. 2000;63:165–71.
  82. Landreh L, Stukenborg JB, Soder O, Svechnikov K. Phenotype and steroidogenic potential of PDGFR $\alpha$ -positive rat neonatal peritubular cells. *Mol Cell Endocrinol* 2013;372:96–104. doi:[10.1016/j.mce.2013.03.019](https://doi.org/10.1016/j.mce.2013.03.019) S0303-7207(13)00115-9 [pii].
  83. O'Shaughnessy PJ, Morris ID, Baker PJ. Leydig cell re-generation and expression of cell signaling molecules in the germ cell-free testis. *Reproduction*. 2008;135:851–8.
  84. Ge RS, Dong Q, Sottas CM, Papadopoulos V, Zirkin BR, Hardy MP. In search of rat stem Leydig cells: Identification, isolation, and lineage-specific development. *Proc Natl Acad Sci U S A*. 2006.
  85. Hardy MP, Zirkin BR, Ewing LL. Kinetic studies on the development of the adult population of Leydig cells in testes of the pubertal rat. *Endocrinology*. 1989;124:762–70.
  86. Park SY, Tong M, Jameson JL. Distinct roles for steroidogenic factor 1 and desert hedgehog pathways in fetal and adult Leydig cell development. *Endocrinology* 2007.
  87. Li X, Wang Z, Jiang Z, Guo J, Zhang Y, Li C, Chung J, Folmer J, Liu J, Lian Q, Ge R, Zirkin BR, Chen H. Regulation of seminiferous tubule-associated stem Leydig cells in adult rat testes. *Proc Natl Acad Sci U S A*. 2016 doi:[10.1073/pnas.1519395113](https://doi.org/10.1073/pnas.1519395113) 1519395113 [pii].
  88. Racine C, Rey R, Forest MG, Louis F, Ferre A, Huhtaniemi I, Jossen N, di Clemente N. Receptors for anti-müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. *Proc Natl Acad Sci U S A*. 1995;95:594–9.
  89. Qin J, Tsai MJ, Tsai SY. Essential roles of COUP-TFII in Leydig cell differentiation and male fertility. *PLoS ONE*. 2008;3:e3285.
  90. Gnassi L, Basciani S, Mariani S, Arizzi M, Spera G, Wang C, Bondjers C, Karlsson L, Betsholtz C. Leydig cell loss and spermatogenic arrest in



- platelet-derived growth factor (PDGF)-A-deficient mice. *J Cell Biol.* 2000;149:1019–26.
91. Schmahl J, Rizzolo K, Soriano P. The PDGF signaling pathway controls multiple steroid-producing lineages. *Genes Dev* 2008;22:3255–267. doi:[10.1101/gad.1723908](https://doi.org/10.1101/gad.1723908) 22/23/3255 [pii].
  92. Basciani S, Mariani S, Spera G, Gnassi L. Role of platelet-derived growth factors in the testis. *Endocr Rev* 2010;31:916–39. doi:[10.1210/er.2010-0004](https://doi.org/10.1210/er.2010-0004) [pii].
  93. Gnassi L, Emidi A, Jannini EA, Carosa E, Maroder M, Arizzi M, Ulisse S, Spera G. Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action. *J Cell Biol.* 1995;131:1105–21.
  94. Mendis-Handagama SM, Ariyaratne HB. Differentiation of the adult Leydig cell population in the postnatal testis. *Biol Reprod.* 2001;65:660–71.
  95. Zhang FP, Pakarainen T, Zhu F, Poutanen M, Huhtaniemi I. Molecular characterization of postnatal development of testicular steroidogenesis in luteinizing hormone receptor knockout mice. *Endocrinology.* 2004;145:1453–63.
  96. Baker PJ, Johnston H, Abel MH, Charlton HM, O'Shaughnessy PJ. Differentiation of adult-type Leydig cells occurs in gonadotrophin-deficient mice. *Reprod Biol Endocrinol.* 2003;1:4.
  97. Baker PJ, O'Shaughnessy PJ. Role of gonadotrophins in regulating numbers of Leydig and Sertoli cells during fetal and postnatal development in mice. *Reproduction.* 2001;122:227–34.
  98. McGee SR, Narayan P. Precocious puberty and Leydig cell hyperplasia in male mice with a gain of function mutation in the LH receptor gene. *Endocrinology* 2013;154:3900–913. doi:[10.1210/en.2012-2179](https://doi.org/10.1210/en.2012-2179) [pii].
  99. O'Shaughnessy PJ, Johnston H, Willerton L, Baker PJ. Failure of normal adult Leydig cell development in androgen-receptor-deficient mice. *J Cell Sci.* 2002;115:3491–6.
  100. De Gendt K, Atanassova N, Tan KA, De Franca LR, Parreira GG, McKinnell C, Sharpe RM, Saunders PT, Mason J, Hartung S, Ivell R, Denolet E, Verhoeven G. Development and function of the adult generation of Leydig cells in mice with Sertoli cell-selective (SCARKO) or total (ARKO) ablation of the androgen receptor. *Endocrinology.* 2005;146:4117–26.
  101. O'Hara L, McInnes K, Simitsidellis I, Morgan S, Atanassova N, Slowikowska-Hilczek J, Kula K, Szarras-Czapnik M, Milne L, Mitchell RT, Smith LB. Autocrine androgen action is essential for Leydig cell maturation and function, and protects against late-onset Leydig cell apoptosis in both mice and men. *FASEB J* 2015;29:894–910. doi:[10.1096/fj.14-255729](https://doi.org/10.1096/fj.14-255729) [pii].
  102. Boyar RM, Moore RJ, Rosner W, Aiman J, Chipman J, Madden JD, Marks JF, Griffin JE. Studies of gonadotropin-gonadal dynamics in patients with androgen insensitivity. *J Clin Endocrinol Metab.* 1978;47:1116–22. doi:[10.1210/jcem-47-5-1116](https://doi.org/10.1210/jcem-47-5-1116).
  103. Judd HL, Hamilton CR, Barlow JJ, Yen SS, Kliman B. Androgen and gonadotropin dynamics in testicular feminization syndrome. *J Clin Endocrinol Metab.* 1972;34:229–34. doi:[10.1210/jcem-34-1-229](https://doi.org/10.1210/jcem-34-1-229).
  104. Nusynowitz ML, Strader WJ III. Regulation of gonadotropin response in testicular feminization syndrome. *Am J Med Sci.* 1975;270:491–6.
  105. Tremblay RR, Foley TP Jr, Corvol P, Park JJ, Kowarski A, Blizzard RM, Jones HW Jr, Migeon CJ. Plasma concentration of testosterone, dihydrotestosterone, testosterone-oestradiol binding globulin, and pituitary gonadotrophins in the syndrome of male pseudo-hermaphroditism with testicular feminization. *Acta Endocrinol (Copenh).* 1972;70:331–41.
  106. Murphy L, O'Shaughnessy PJ. Testicular steroidogenesis in the testicular feminized (Tfm) mouse: loss of 17 $\alpha$ -hydroxylase activity. *J Endocrinol.* 1991;131:443–9.
  107. Wilson SC, Oakey RE, Scott JS. Steroid metabolism in testes of patients with incomplete masculinization due to androgen insensitivity or 17 $\beta$ -hydroxysteroid dehydrogenase deficiency and normally differentiated males. *J Steroid Biochem.* 1988;29:649–55.
  108. Kilcoyne KR, Smith LB, Atanassova N, MacPherson S, McKinnell C, van den Driesche S, Jobling MS, Chambers TJ, De GK, Verhoeven G, O'Hara L, Platts S, Renato de FL, Lara NL, Anderson RA, Sharpe RM. Fetal programming of adult Leydig cell function by androgenic effects on stem/progenitor cells. *Proc Natl Acad Sci U S A* 2014;111:E1924–932. doi:[10.1073/pnas.1320735111](https://doi.org/10.1073/pnas.1320735111) [pii].
  109. Eisenberg ML, Jensen TK, Walters RC, Skakkebaek NE, Lipshultz LI. The relationship between anogenital distance and reproductive hormone levels in adult men. *J Urol* 2012;187:594–98. doi:[10.1016/j.juro.2011.10.041](https://doi.org/10.1016/j.juro.2011.10.041) [pii].
  110. Smith LB, Walker WH. Hormone signalling in the testis. In: Plant TM, Zeleznick AJ, editors. *Knobil and Neill's physiology of reproduction*. Amsterdam: Elsevier; 2015. p. 637–90.
  111. Hansson V, Skälhegg BS, Tasken K. Cyclic-AMP-dependent protein kinase (PKA) in testicular cells. Cell specific expression, differential regulation and targeting of subunits of PKA. *J Steroid Biochem Mol Biol* 2000;73:81–92. doi:[10.1016/S0960-0760\(00\)00057-1](https://doi.org/10.1016/S0960-0760(00)00057-1) [pii].
  112. Manna PR, Huhtaniemi IT, Stocco DM. Mechanisms of protein kinase C signaling in the modulation of 3',5'-cyclic adenosine monophosphate-mediated steroidogenesis in mouse gonadal cells. *Endocrinology* 2009;150:3308–317. doi:[10.1210/en.2008-1668](https://doi.org/10.1210/en.2008-1668) [pii].
  113. Costa RR, Varanda WA, Franci CR. A calcium-induced calcium release mechanism supports luteinizing hormone-induced testosterone

- secretion in mouse Leydig cells. *Am J Physiol Cell Physiol* 2010;299:C316-23. doi:[10.1152/ajpcell.00521.2009](#) ajpcell.00521.2009 [pii].
114. Abdou HS, Villeneuve G, Tremblay JJ The calcium signaling pathway regulates leydig cell steroidogenesis through a transcriptional cascade involving the nuclear receptor NR4A1 and the steroidogenic acute regulatory protein. *Endocrinology* 2013;154:511-20. doi:[10.1210/en.2012-1767](#) en.2012-1767 [pii].
  115. Evaul K, Hammes SR Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells. *J Biol Chem* 2008;283:27525-7533. doi:[10.1074/jbc.M803867200](#) M803867200 [pii].
  116. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolsheimer E, Jacobsen E, Kadam S, Ecker JR, Emerson B, Hogenesch JB, Unterman T, Young RA, Montminy M Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. *Proc Natl Acad Sci U S A* 2005;102:4459-464. doi:[10.1073/pnas.0501076102](#) 0501076102 [pii].
  117. Manna PR, Eubank DW, Lalli E, Sassone-Corsi P, Stocco DM. Transcriptional regulation of the mouse steroidogenic acute regulatory protein gene by the cAMP response-element binding protein and steroidogenic factor 1. *J Mol Endocrinol*. 2003;30:381-97.
  118. Scott IS, Charlton HM, Cox BS, Grocock CA, Sheffield JW, O'Shaughnessy PJ. Effect of LH injections on testicular steroidogenesis, cholesterol side-chain cleavage P450 messenger RNA content and leydig cell morphology in hypogonadal mice. *J Endocrinol*. 1990;125:131-8.
  119. O'Shaughnessy PJ, Fleming LM, Jackson G, Hochgeschwender U, Reed P, Baker PJ. Adrenocorticotrophic hormone directly stimulates testosterone production by the fetal and neonatal mouse testis. *Endocrinology*. 2003;144:3279-84.
  120. Johnston H, King PJ, O'Shaughnessy PJ. Effects of ACTH and expression of the melanocortin-2 receptor in the neonatal mouse testis. *Reproduction*. 2007;133:1181-7.
  121. O'Shaughnessy PJ, Morris ID, Huhtaniemi I, Baker PJ, Abel MH. Role of androgen and gonadotrophins in the development and function of the Sertoli cells and Leydig cells: Data from mutant and genetically modified mice. *Mol Cell Endocrinol*. 2009;306:2-8.
  122. Hatano O, Takakusu A, Nomura M, Morohashi K. Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1. *Genes Cells*. 1996;1:663-71.
  123. Hu L, Monteiro A, Johnston H, King P, O'Shaughnessy PJ. Expression of Cyp21a1 and Cyp11b1 in the fetal mouse testis. *Reproduction*. 2007;134:585-91.
  124. O'Shaughnessy PJ, Baker PJ, Johnston H. The foetal Leydig cell—differentiation, function and regulation. *Int J Androl*. 2006;29:90-5.
  125. Val P, Jeays-Ward K, Swain A. Identification of a novel population of adrenal-like cells in the mammalian testis. *Dev Biol*. 2006;299:250-6.
  126. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM, Sweep FC, Hermus AR Testicular adrenal rest tumours in congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab* 2009;23:209-20. doi:[10.1016/j.beem.2008.09.007](#) S1521-690X(08)00105-X [pii].
  127. El Gehani F, Tena-Sempere M, Ruskoaho H, Huhtaniemi I. Natriuretic peptides stimulate steroidogenesis in the fetal rat testis. *Biol Reprod*. 2001;65:595-600.
  128. El Gehani F, Tena-Sempere M, Huhtaniemi I. Evidence that pituitary adenylate cyclase-activating polypeptide is a potent regulator of fetal rat testicular steroidogenesis. *Biol Reprod*. 2000;63:1482-9.
  129. El Gehani F, Tena-Sempere M, Huhtaniemi I. Vasoactive intestinal peptide stimulates testosterone production by cultured fetal rat testicular cells. *Mol Cell Endocrinol*. 1998;140:175-8.
  130. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G Endocrine regulation of male fertility by the skeleton. *Cell* 2011;144: 796-809. doi:[10.1016/j.cell.2011.02.004](#) S0092-8674(11)00118-8 [pii].
  131. Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, Srinivas P, Chamouni A, Lugani F, Lejeune H, Kumar TR, Plotton I, Karsenty G Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. *J Clin Invest* 2013;123:2421-433. doi:[10.1172/JCI65952](#) 65952 [pii].
  132. Karsenty G, Oury F Regulation of male fertility by the bone-derived hormone osteocalcin. *Mol Cell Endocrinol* 2014;382:521-26. doi:[10.1016/j.mce.2013.10.008](#) S0303-7207(13)00448-6 [pii].
  133. Chen YI, Payne AH, Kelch RP. FSH stimulation of Leydig cell function in the hypophysectomized immature rat. *Proc Soc Exp Biol Med*. 1976;153:473-5.
  134. Lapolt PS, Tilly JL, Aihara T, Nishimori K, Hsueh AJW. Gonadotropin-induced up-regulation and down-regulation of ovarian follicle-stimulating-hormone (fsh) receptor gene- expression in immature rats—effects of pregnant mares serum gonadotropin, human chorionic-gonadotropin, and recombinant fsh. *Endocrinology*. 1992;130:1289-95.
  135. Sadate-Ngatchou PI, Pouchnik DJ, Griswold MD. Follicle-stimulating hormone induced changes in

- gene expression of murine testis. *Mol Endocrinol*. 2004;18:2805–16.
136. Baker PJ, Pakarinen P, Huhtaniemi IT, Abel MH, Charlton HM, Kumar TR, O'Shaughnessy PJ. Failure of normal leydig cell development in follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSH $\beta$ -deficient mice: role for constitutive FSH receptor activity. *Endocrinology*. 2003;144:138–45.
  137. Abel M, Baban D, Lee S, Charlton H, O'Shaughnessy P. Effects of follicle stimulating hormone on testicular mRNA transcript levels in the hypogonadal mouse. *J Mol Endocrinol*. 2009;42:291–303.
  138. Young J, Couzinet B, Chanson P, Brailly S, Loumaye E, Schaison G. Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions. *J Clin Endocrinol Metab*. 2000;85:3239–44.
  139. Lofrano-Porto A, Casulari LA, Nascimento PP, Giacomini L, Naves LA, da Motta LD, Layman LC. Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation. *Fertil Steril*. 2008;90:1169–74.
  140. Levalle O, Zylbersztein C, Aszpis S, Aquilano D, Terradas C, Colombani M, Aranda C, Scaglia H. Recombinant human follicle-stimulating hormone administration increases testosterone production in men, possibly by a Sertoli cell-secreted nonsteroid factor. *J Clin Endocrinol Metab*. 1998;83:3973–6.
  141. Heckert LL, Griswold MD. The expression of the follicle-stimulating hormone receptor in spermatogenesis. *Recent Prog Horm Res*. 2002;57:129–48.
  142. Rebourcet D, O'Shaughnessy PJ, Monteiro A, Milne L, Cruickshanks L, Jeffrey N, Guillou F, Freeman TC, Mitchell RT, Smith LB. Sertoli cells maintain Leydig cell number and peritubular myoid cell activity in the adult mouse testis. *PLoS ONE*. 2014;9:e105687. doi:[10.1371/journal.pone.0105687](https://doi.org/10.1371/journal.pone.0105687) PONE-D-14-19027 [pii].
  143. Huhtaniemi I Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. *Asian J Androl* 2014;16:192–202. doi:[10.4103/1008-682X.122336](https://doi.org/10.4103/1008-682X.122336) 122336 [pii].
  144. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. *J Clin Endocrinol Metab* 2007;92:549–55. doi:[10.1210/jc.2006-1859](https://doi.org/10.1210/jc.2006-1859) jc.2006-1859 [pii].
  145. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. *J Clin Endocrinol Metab* 2008;93: 2737–745. doi:[10.1210/jc.2007-1972](https://doi.org/10.1210/jc.2007-1972) jc.2007-1972 [pii].
  146. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Aging Study. *J Clin Endocrinol Metab* 2010;95:1810–818. doi:[10.1210/jc.2009-1796](https://doi.org/10.1210/jc.2009-1796) jc.2009-1796 [pii].
  147. Coviello AD, Lakshman K, Mazer NA, Bhasin S Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. *J Clin Endocrinol Metab* 2006; 91:4669–675. doi:[10.1210/jc.2006-0822](https://doi.org/10.1210/jc.2006-0822) jc.2006-0822 [pii].
  148. Veldhuis JD, Liu PY, Keenan DM, Takahashi PY Older men exhibit reduced efficacy of and heightened potency downregulation by intravenous pulses of recombinant human LH: a study in 92 healthy men. *Am J Physiol Endocrinol Metab* 2012;302: E117-22. doi:[10.1152/ajpendo.00450.2011](https://doi.org/10.1152/ajpendo.00450.2011) ajpendo.00450.2011 [pii].
  149. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. *J Clin Endocrinol Metab*. 1987;65:1118–26. doi:[10.1210/jcem-65-6-1118](https://doi.org/10.1210/jcem-65-6-1118).
  150. Neaves WB, Johnson L, Porter JC, Parker CR Jr, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. *J Clin Endocrinol Metab*. 1984;59:756–63. doi:[10.1210/jcem-59-4-756](https://doi.org/10.1210/jcem-59-4-756).
  151. Kaler LW, Neaves WB. Attrition of the human Leydig cell population with advancing age. *Anat Rec*. 1978;192:513–8. doi:[10.1002/ar.1091920405](https://doi.org/10.1002/ar.1091920405).
  152. Harbitz TB. Morphometric studies of the Leydig cells in elderly men with special reference to the histology of the prostate. An analysis in an autopsy series. *Acta Pathol Microbiol Scand A*. 1973;81:301–14.
  153. Paniagua R, Martin A, Nistal M, Amat P. Testicular involution in elderly men: comparison of histologic quantitative studies with hormone patterns. *Fertil Steril*. 1987;47:671–9.
  154. Petersen PM, Seieroe K, Pakkenberg B. The total number of Leydig and Sertoli cells in the testes of men across various age groups—a stereological study. *J Anat*. 2015;226:175–9. doi:[10.1111/joa.12261](https://doi.org/10.1111/joa.12261).
  155. Paniagua R, Nistal M, Saez FJ, Fraile B. Ultrastructure of the aging human testis. *J Electron Microscop Tech*. 1991;19:241–60.

156. Nistal M, Santamaria L, Paniagua R, Regadera J, Codesal J. Multinucleate leydig-cells in normal human testes. *Andrologia*. 1986;18:268–72.
157. Mori H, Hiromoto N, Nakahara M, Shiraishi T. Stereological analysis of Leydig cell ultrastructure in aged humans. *J Clin Endocrinol Metab*. 1982;55:634–41. doi:[10.1210/jcem-55-4-634](https://doi.org/10.1210/jcem-55-4-634).
158. Takahashi J, Higashi Y, LaNasa JA, Yoshida K, Winters SJ, Oshima H, Troen P. Studies of the human testis. XVIII. Simultaneous measurement of nine intratesticular steroids: evidence for reduced mitochondrial function in testis of elderly men. *J Clin Endocrinol Metab*. 1983;56:1178–87. doi:[10.1210/jcem-56-6-1178](https://doi.org/10.1210/jcem-56-6-1178).
159. Beattie MC, Adekola L, Papadopoulos V, Chen H, Zirkin BR. Leydig cell aging and hypogonadism. *Exp Gerontol*. 2015 doi:[10.1016/j.exger.2015.02.014](https://doi.org/10.1016/j.exger.2015.02.014) S0531-5565(15)00076-5 [pii].
160. Chen H, Guo J, Ge R, Lian Q, Papadopoulos V, Zirkin BR. Steroidogenic fate of the Leydig cells that repopulate the testes of young and aged Brown Norway rats after elimination of the preexisting Leydig cells. *Exp Gerontol* 2015;72:8–15. doi:[10.1016/j.exger.2015.08.014](https://doi.org/10.1016/j.exger.2015.08.014) S0531-5565(15)30038-3 [pii].
161. Woodward PJ, Sohaey R, O'Donoghue MJ, Green DE. From the archives of the AFIP: tumors and tumorlike lesions of the testis: radiologic-pathologic correlation. *Radiographics*. 2002;22:189–216. doi:[10.1148/radiographics.22.1.g02ja14189](https://doi.org/10.1148/radiographics.22.1.g02ja14189).
162. Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. *Am J Surg Pathol*. 1985;9:177–92.
163. Maizlin ZV, Belenky A, Kunichezky M, Sandbank J, Strauss S. Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance. *J Ultrasound Med* 2004;23:959–64. 23/7/959 [pii].
164. Cortez JC, Kaplan GW. Gonadal stromal tumors, gonadoblastomas, epidermoid cysts, and secondary tumors of the testis in children. *Urol Clin North Am*. 1993;20:15–26.
165. Al-Agha OM, Axiotis CA. An in-depth look at Leydig cell tumor of the testis. *Arch Pathol Lab Med* 2007;131:311–17. doi:[10.1043/1543-2165\(2007\)131\[311:AILALC\]2.0.CO;2](https://doi.org/10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2) RS6-0240 [pii].
166. Ducharme JR, Collu R. Pubertal development: normal, precocious and delayed. *Clin Endocrinol Metab*. 1982;11:57–87.
167. Leonhartsberger N, Ramoner R, Aigner F, Stoehr B, Pichler R, Zangerl F, Fritzer A, Steiner H. Increased incidence of Leydig cell tumours of the testis in the era of improved imaging techniques. *BJU Int*. 2011;108:1603–7. doi:[10.1111/j.1464-410X.2011.10177.x](https://doi.org/10.1111/j.1464-410X.2011.10177.x).
168. Lock G, Schmidt C, Helmich F, Stolle E, Dieckmann KP. Early experience with contrast-enhanced ultrasound in the diagnosis of testicular masses: a feasibility study. *Urology* 2011;77:1049–053. doi:[10.1016/j.urology.2010.12.035](https://doi.org/10.1016/j.urology.2010.12.035) S0090-4295(10)02173-4 [pii].
169. Richmond I, Banerjee SS, Eyden BP, Sissons MC. Sarcomatoid Leydig cell tumour of testis. *Histopathology*. 1995;27:578–80.
170. Ritchie JP. Neoplasms of the testis. In: Walsh P, Reitik A, Vaughan E, Wein A, editors. *Campbell's Urology*. Philadelphia: WB Saunders; 1992. p. 1222–63.
171. Bozzini G, Picozzi S, Gadda F, Colombo R, Decobelli O, Palou J, Colpi G, Carmignani L. Long-term follow-up using testicle-sparing surgery for Leydig cell tumor. *Clin Genitourin Cancer* 2013;11:321–24. doi:[10.1016/j.clgc.2012.12.008](https://doi.org/10.1016/j.clgc.2012.12.008) S1558-7673(12)00247-9 [pii].
172. Chandak P, Shah A, Taghizadeh A, Tiptaft R, Dasgupta P. Testis-sparing surgery for benign and malignant testicular tumours. *Int J Clin Pract*. 2003;57:912–3.
173. Bertram KA, Bratloff B, Hodges GF, Davidson H. Treatment of malignant Leydig cell tumor. *Cancer*. 1991;68:2324–9.
174. Olivier P, Simoneau-Roy J, Francoeur D, Sartelet H, Parma J, Vassart G, Van VG. Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. *J Pediatr* 2012;161:1147–52. doi:[10.1016/j.jpeds.2012.05.039](https://doi.org/10.1016/j.jpeds.2012.05.039) S0022-3476(12)00556-2 [pii].
175. Ahtiainen P, Rulli SB, Shariatmadari R, Pelliniemi LJ, Toppari J, Poutanen M, Huh-taniemi IT. Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. *Oncogene* 2005;24:7301–309. doi:[10.1038/sj.onc.1208893](https://doi.org/10.1038/sj.onc.1208893) 1208893 [pii].
176. Makabe S, Naguro T, Heyn R, Motta PM. Ultrastructure of human Leydig cells at early gonadal embryogenesis. *Ital J Anat Embryol*. 1995;100(Suppl 1):525–33.
177. Basciani S, Brama M, Mariani S, De LG, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnassi L. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. *Cancer Res* 2005;65:1897–903. doi:[10.1158/0008-5472.CAN-04-2181](https://doi.org/10.1158/0008-5472.CAN-04-2181) 65/5/1897 [pii].
178. Froehner M, Beuthien-Baumann B, Dittert DD, Schuler U, Wirth MP. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. *Cancer Chemother Pharmacol*. 2006;58:716–8. doi:[10.1007/s00280-005-0181-6](https://doi.org/10.1007/s00280-005-0181-6).
179. Naughton CK, Nadler RB, Basler JW, Humphrey PA. Leydig cell hyperplasia. *Br J Urol*. 1998;81:282–9.
180. Tash JA, McCallum S, Hardy MP, Knudsen B, Schlegel PN. Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia. *J Urol*. 2002;168:1068–70. doi:[10.1097/01.ju](https://doi.org/10.1097/01.ju)

- 0000026414.68954.d1 S0022-5347(05)64576-4 [pii].
181. Habert R, Livera G, Rouiller-fabre V. Man is not a big rat: concerns with traditional human risk assessment of phthalates based on their anti-androgenic effects observed in the rat foetus. *Basic Clin Androl*. 2014;24:14. doi:[10.1186/2051-4190-24-14](#) 27 [pii].
  182. van den Driesche S, Walker M, McKinnell C, Scott HM, Eddie SL, Mitchell RT, Seckl JR, Drake AJ, Smith LB, Anderson RA, Sharpe RM. Proposed role for COUP-TFII in regulating fetal Leydig cell steroidogenesis, perturbation of which leads to masculinization disorders in rodents. *PLoS ONE*. 2012;7:e37064. doi:[10.1371/journal.pone.0037064](#) PONE-D-12-03035 [pii].
  183. Svechnikov K, Savchuk I, Morvan ML, Antignac JP, Le BB, Soder O Phthalates exert multiple effects on Leydig cell steroidogenesis. *Horm Res Paediatr*. 2015; 000440619 doi:[10.1159/000440619](#).
  184. Desdoits-Lethimonier C, Albert O, Le BB, Perdu E, Zalko D, Courant F, Lesne L, Guille F, Dejucq-Rainsford N, Jegou B Human testis steroidogenesis is inhibited by phthalates. *Hum Reprod* 2012;27:1451–459. doi:[10.1093/humrep/des069](#) des069 [pii].
  185. N'Tumba-Byn T, Moison D, Lacroix M, Lecureuil C, Lesage L, Prud'homme SM, Pozzi-Gaudin S, Frydman R, Benachi A, Livera G, Rouiller-fabre V, Habert R. Differential effects of bisphenol A and diethylstilbestrol on human, rat and mouse fetal leydig cell function. *PLoS ONE*. 2012;7:e51579. doi:[10.1371/journal.pone.0051579](#) PONE-D-12-19171 [pii].
  186. Ben MM, Lesne L, Desdoits-Lethimonier C, Coiffec I, Lassarguere J, Lavoue V, Deceuninck Y, Antignac JP, Le BB, Perdu E, Zalko D, Pineau C, Chevrier C, Dejucq-Rainsford N, Mazaud-Guittot S, Jegou B. An investigation of the endocrine-disruptive effects of bisphenol a in human and rat fetal testes. *PLoS ONE*. 2015;10:e0117226. doi:[10.1371/journal.pone.0117226](#) PONE-D-14-40771 [pii].
  187. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. *BMC Med* 2013;11:57. doi:[10.1186/1741-7015-11-57](#) 1741–7015-11-57 [pii].
  188. Klinefelter GR, Laskey JW, Amann RP Statin drugs markedly inhibit testosterone production by rat Leydig cells in vitro: implications for men. *Reprod Toxicol* 2014;45:52–8. doi:[10.1016/j.reprotox.2013.12.010](#) S0890-6238(14)00007-0 [pii].
  189. Beverly BE, Lambright CS, Furr JR, Sampson H, Wilson VS, McIntyre BS, Foster PM, Travlos G, Gray LE, Jr Simvastatin and dipentyl phthalate lower ex vivo testicular testosterone production and exhibit additive effects on testicular testosterone and gene expression via distinct mechanistic pathways in the fetal rat. *Toxicol Sci* 2014;141:524–37. doi:[10.1093/toxsci/kfu149](#) kfu149 [pii].
  190. Van Thiel DH, Lester R, Sherins RJ. Hypogonadism in alcoholic liver disease: evidence for a double defect. *Gastroenterology*. 1974;67:1188–99.
  191. Maneesh M, Dutta S, Chakrabarti A, Vasudevan DM. Alcohol abuse-duration dependent decrease in plasma testosterone and antioxidants in males. *Indian J Physiol Pharmacol*. 2006;50:291–6.
  192. Santori C, Ceccanti M, Diacinti D, Attilia ML, Toppo L, D'Erasmo E, Romagnoli E, Mascia ML, Cipriani C, Prastaro A, Carnevale V, Minisola S Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. *J Endocrinol Invest* 2008;31:321–26. doi:[10.1007/BF03346365](#) 4564 [pii].
  193. Muthusami KR, Chinnaswamy P Effect of chronic alcoholism on male fertility hormones and semen quality. *Fertil Steril* 2005;84:919–24. doi:[10.1016/j.fertnstert.2005.04.025](#) S0015-0282(05)01251-3 [pii].
  194. Smith LB, O'Shaughnessy PJ, Rebourcet D. Cell-specific ablation in the testis: what have we learned? *Andrology*. 2015;3:1035–49. doi:[10.1111/andr.12107](#).
  195. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. *J Clin Endocrinol Metab*. 2007;92:3568–72.
  196. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab*. 2008;93:68–75.
  197. Saad F, Gooren LJ The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. *J Obes* 2011.
  198. Barker DJ. The origins of the developmental origins theory. *J Intern Med*. 2007;261:412–7.
  199. Vanbillemont G, Lapauw B, Bogaert V, De Naeyer H, De Bacquer D, Ruige J, Kaufman JM, Taes YE. Birth weight in relation to sex steroid status and body composition in young healthy male siblings. *J Clin Endocrinol Metab*. 2010;95:1587–94.
  200. Prince FP Mitochondrial cristae diversity in human Leydig cells: a revised look at cristae morphology in these steroid-producing cells. *Anat Rec* 1999; 254:534–41. doi:[10.1002/\(SICI\)1097-0185\(19990401\)254:4<534::AID-AR8>3.0.CO;2-#](#).



**Male Hypogonadism**

Basic, Clinical and Therapeutic Principles

Winters, S.; Huhtaniemi, I.T. (Eds.)

2017, XIV, 446 p. 90 illus., 42 illus. in color., Hardcover

ISBN: 978-3-319-53296-7

A product of Humana Press